ABOUT US

 

EVOQ (ee-voke) Therapeutics is a cancer immunotherapy company with a mission to improve outcomes for patients by unleashing the full potential of cancer vaccines

Employing the power of the immune system to target and eliminate cancerous cells has revolutionized cancer therapy in the 21st century. However, despite significant advances across a range of therapeutic approaches, we are still far from harnessing the full power and potential of immuno-oncology in the fight against cancer.

EVOQ Therapeutics is pioneering the development of a proprietary platform that represents a genuine breakthrough in cancer vaccine technology. EVOQ has demonstrated that delivering antigens and adjuvants via our synthetic high-density lipoprotein (sHDL) NanoDisc Vaccine produces an immune response that is 30 times more powerful than the best antigen adjuvant combinations. With EVOQ’s breakthrough technology, and recent discoveries of novel shared neo-antigens in brain cancer – the promise of safe and effective cancer vaccines for patients suffering from this devastating disease is now within reach
 

Our company is built on a foundation of innovation; and our Leadership Team has the necessary experience in drug development, commercialization, and value creation to unleash the full power and potential of cancer vaccines to improve the lives of patients. 

OUR LEADERSHIP

William Brinkerhoff
Co-Founder and Chief Executive Officer

Bill has more than 20 years of experience in the pharmaceutical and biotech industry focused in new product planning, corporate development, business development and licensing. He was president of AlphaCore Pharma prior to the company’s acquisition by Astra Zeneca in March 2013. He was co-founder and chief operating officer of Cerenis Therapeutics from 2005-2011. Previously he was vice president of business development at Esperion Therapeutics, overseeing all strategic partnering activities prior to the company’s acquisition by Pfizer. Prior to joining Esperion, he oversaw U.S. business development, market planning and sales operations for Sankyo, a leading Japanese pharmaceutical company (now Daiichi Sankyo).

Greg Barrett
President

Greg has nearly 30 years of experience in the pharmaceutical/biotechnology industry. He was President of the US commercial division of Daiichi Sankyo Inc. (a global Japanese pharmaceutical company with 2,500 US employees). He has served as the head of commercial operations, marketing, managed markets... and launched over ten brands across a wide range therapeutic classes. He has chaired multiple co-development and co-marketing partnerships with organizations like Eli Lilly, Forest, AstraZeneca, and Parke-Davis. Earlier in his career, he managed the alpha interferon franchise in the Global and US divisions of Schering-Plough. He also worked in Biologics R&D, Oncology Clinical Development, Vaccine & Cardiovascular Sales and Commercial Analytics at Lederle Laboratories.

James Moon, PhD
Co-Founder and Chief Scientific Officer

Dr. James Moon is the John Gideon Searle Associate Professor in the Department of Pharmaceutical Sciences and Biomedical Engineering at University of Michigan, Ann Arbor.     He is also a member of the University of Michigan Comprehensive Cancer Center. His translational research program aims to improve vaccines and immunotherapies. He has received numerous awards, including 2017 Emerald Foundation Distinguished Investigator Award, 2016 NSF CAREER Award, and 2016 DOD Career Development Award. Dr. Moon received his bachelor’s degree from the University of California, Berkeley, and his Ph.D. from Rice University, and he completed his postdoctoral training at MIT.

Anna Schwendeman, PhD
Co-Founder and Vice President of Preclinical Development

Dr. Anna Schwendeman is an Associate Professor in the Department of Pharmaceutical Sciences at University of Michigan, Ann Arbor. She spent 12 years in pharmaceutical industry at Cerenis Therapeutics (Fierce 15 biotech), Pfizer, and Esperion Therapeutics. She was involved in the discovery and translation of several HDL therapies to Phase II clinical trials. Her efforts led to the development of a kilo-scale recombinant Apolipoprotein A-I process and highly homogeneous and safe HDL particles. She successfully submitted FDA INDs for six different products, including nanoparticles, liposomes, proteins, peptides and small molecules.